The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem cell technology will be acquired by PreCerv from Hemostemix.
Hemostemix is a publicly traded biotechnology company listed on OTC. Today it has recorded a market opening price of $0.2151.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $172K+ in the last 3 months. The average volume of the company in the last 10 days is $97K with $190.16M share outstanding. The stock price when the market opened was $0.05.
$IBO is gliding swiftly on the TSX-V Index, the shares are trading currently at $0.05 which might get doubled in the upcoming days or week maximum.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike Hemostemix hires new financial advisor to the family Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has...
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.
Hemostemix Inc. is a publicly traded biotechnology company listed on TSX-V marked with an opening of $0.285.
Hemostemix Inc. is a biotechnology company listed on TSX-V with ticker symbol $HEM has shown growth in its volume. Today the volume is $8.62K.
Julie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
Universal Ibogaine Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0258-$0.1143 in the last 52 weeks.
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of 138 K+ in the last 50 days . The average volume of the company in the last 10 days is $88.98K with $190.74M share outstanding. The stock price when the market opened was $0.05
Universal Ibogaine Inc. is a life science company listed on OTC with the ticker symbol $IBOGF. In the last 52 weeks the range of the lower and upper price is $0.0258-$0.1143.
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery. While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.